ANV419 IS A NOVEL CD122-SELECTIVE IL-2/ANTI-IL-2 ANTIBODY FUSION PROTEIN WITH POTENT CD8 T CELL AND NK CELL STIMULATORY FUNCTION IN VITRO AND IN VIVO

被引：0
|
作者：
Huber, Christoph [1 ]
Katopodis, Andreas [1 ]
Branetti, Barbara [2 ]
Rondeau, Jean-Michel [2 ]
Popp, Simone [2 ]
Regnier, Catherine [2 ]
Kaiser, Daniel [2 ]
机构：
[1] Anaveon AG, Basel, Switzerland
[2] NIBR, Cambridge, MA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
571
引用
收藏
页码：A343 / A343
页数：1
相关论文
共 50 条
  • [1] ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity
    Richter, K.
    Egli, N.
    Petersen, L.
    Murer, P.
    Katopodis, A. G.
    Huber, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S558 - S558
  • [2] Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+T and natural killer cell-stimulating capacity for cancer immunotherapy
    Murer, Patrizia
    Brannetti, Barbara
    Rondeau, Jean-Michel
    Petersen, Laetitia
    Egli, Nicole
    Popp, Simone
    Regnier, Catherine
    Richter, Kirsten
    Katopodis, Andreas
    Huber, Christoph
    [J]. MABS, 2024, 16 (01)
  • [3] CD122-selective IL-2/anti-IL-2 complexes reduce regulatory T cell function and promote CD8+ T cell polyfunctionality for durable ovarian cancer immunotherapy
    Drerup, Justin M.
    Pandeswara, Sri Lakshmi
    Liu, Aijie
    Clark, Curtis A.
    Padron, Alvaro S.
    Chen, Wanjiao
    Hurez, Vincent
    Curiel, Tyler J.
    [J]. CANCER RESEARCH, 2017, 77
  • [4] ANV419 IS A NOVEL CD122-BIASED IL-2/ANTI-IL-2 FUSION PROTEIN SHOWING INCREASED EFFICACY IN COMBINATION WITH CHECKPOINT INHIBITORS AND TREATMENTS ACTING THROUGH ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY
    Huber, Christoph
    Richter, Kirsten
    Petersen, Laetitia
    Egli, Nicole
    Murer, Patrizia
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1142 - A1142
  • [5] CD122-selective IL-2/anti-IL-2 mAb complex enhances the function of innate and adaptive immunity against cancers
    Shimizu, Kanako
    Ueda, Shogo
    Fujii, Shinichiro
    [J]. CANCER SCIENCE, 2023, 114 : 1193 - 1193
  • [6] In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy
    Tomala, Jakub
    Chmelova, Helena
    Mrkvan, Tomas
    Rihova, Blanka
    Kovar, Marek
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 183 (08): : 4904 - 4912
  • [7] Role of IL-2 in induction of CD8 T cell tolerance by LSEC
    Schurich, A. K.
    Berg, M.
    Limmer, A.
    Schild, H. J.
    Diehl, L.
    Knolle, P. A.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 32 - 32
  • [8] IL-2/Anti-IL-2 Complex: A Novel Strategy of In Vivo Regulatory T Cell Expansion in Renal Injury
    Wang, Yuan Min
    Alexander, Stephen I.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (10): : 1503 - 1504
  • [9] Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion
    Wong, P
    Pamer, EG
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (04): : 2171 - 2176
  • [10] CD122-SELECTIVE IL-2 COMPLEXES TREAT OVARIAN CARCINOMAS, INDUCE TREG FRAGILITY AND PROMOTE T CELL STEM CELLS
    Deng, Yilun
    Drerup, Justin
    Zhang, Xinyue
    Reyes, Ryan
    Mendez, Jenny
    Kancharla, Aravind
    Garcia, Myrna
    Bai, Haiyan
    Padron, Alvaro
    Gupta, Harshita
    Curiel, Tyler
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A414 - A415
12345